Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.68
NVS's Cash to Debt is ranked lower than
70% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. NVS: 0.68 )
Ranked among companies with meaningful Cash to Debt only.
NVS' s 10-Year Cash to Debt Range
Min: 0.25  Med: 1.50 Max: 3.39
Current: 0.68
0.25
3.39
Equity to Asset 0.56
NVS's Equity to Asset is ranked lower than
59% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVS: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
NVS' s 10-Year Equity to Asset Range
Min: 0.51  Med: 0.59 Max: 0.65
Current: 0.56
0.51
0.65
Interest Coverage 15.75
NVS's Interest Coverage is ranked lower than
76% of the 370 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 933.44 vs. NVS: 15.75 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s 10-Year Interest Coverage Range
Min: 13.56  Med: 18.99 Max: 30.91
Current: 15.75
13.56
30.91
F-Score: 6
Z-Score: 4.15
M-Score: -2.81
WACC vs ROIC
8.78%
11.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 20.91
NVS's Operating margin (%) is ranked higher than
83% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. NVS: 20.91 )
Ranked among companies with meaningful Operating margin (%) only.
NVS' s 10-Year Operating margin (%) Range
Min: 17.81  Med: 21.87 Max: 24.34
Current: 20.91
17.81
24.34
Net-margin (%) 39.05
NVS's Net-margin (%) is ranked higher than
96% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. NVS: 39.05 )
Ranked among companies with meaningful Net-margin (%) only.
NVS' s 10-Year Net-margin (%) Range
Min: 15.35  Med: 19.24 Max: 31.38
Current: 39.05
15.35
31.38
ROE (%) 29.05
NVS's ROE (%) is ranked higher than
90% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.87 vs. NVS: 29.05 )
Ranked among companies with meaningful ROE (%) only.
NVS' s 10-Year ROE (%) Range
Min: 12.6  Med: 16.53 Max: 25.73
Current: 29.05
12.6
25.73
ROA (%) 16.39
NVS's ROA (%) is ranked higher than
88% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. NVS: 16.39 )
Ranked among companies with meaningful ROA (%) only.
NVS' s 10-Year ROA (%) Range
Min: 7.21  Med: 10.35 Max: 16.18
Current: 16.39
7.21
16.18
ROC (Joel Greenblatt) (%) 63.37
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.80 vs. NVS: 63.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 43.76  Med: 64.13 Max: 90.24
Current: 63.37
43.76
90.24
Revenue Growth (3Y)(%) -2.00
NVS's Revenue Growth (3Y)(%) is ranked lower than
72% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NVS: -2.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.9  Med: 4.80 Max: 73.5
Current: -2
-3.9
73.5
EBITDA Growth (3Y)(%) 5.40
NVS's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 476 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. NVS: 5.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7  Med: 2.00 Max: 82.8
Current: 5.4
-7
82.8
EPS Growth (3Y)(%) 6.00
NVS's EPS Growth (3Y)(%) is ranked higher than
52% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. NVS: 6.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVS' s 10-Year EPS Growth (3Y)(%) Range
Min: -7.2  Med: 4.80 Max: 82.2
Current: 6
-7.2
82.2
» NVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NVS Guru Trades in Q2 2014

Louis Moore Bacon 180,000 sh (New)
Dodge & Cox 51,102,219 sh (+10.04%)
Manning & Napier Advisors, Inc 332,704 sh (+5.85%)
Ken Fisher 5,969,963 sh (+1.37%)
Pioneer Investments 86,323 sh (+1.08%)
RS Investment Management 76,745 sh (+0.26%)
Murray Stahl 29,425 sh (+0.23%)
First Eagle Investment 13,060 sh (unchged)
Steven Cohen 69,500 sh (unchged)
Bill Frels 4,105 sh (unchged)
Lee Ainslie Sold Out
PRIMECAP Management 23,846,236 sh (-0.70%)
Tweedy Browne 288,825 sh (-0.92%)
John Buckingham 83,941 sh (-1.45%)
Sarah Ketterer 320,852 sh (-1.98%)
John Hussman 214,000 sh (-3.25%)
Mario Gabelli 10,240 sh (-4.66%)
Kahn Brothers 26,368 sh (-6.06%)
HOTCHKIS & WILEY 649,519 sh (-71.80%)
Jim Simons 14,000 sh (-85.42%)
» More
Q3 2014

NVS Guru Trades in Q3 2014

Lee Ainslie 272,570 sh (New)
Ruane Cunniff 7,772 sh (New)
Jim Simons 285,900 sh (+1942.14%)
Kahn Brothers 30,368 sh (+15.17%)
Bill Frels 4,331 sh (+5.51%)
Sarah Ketterer 334,171 sh (+4.15%)
Manning & Napier Advisors, Inc 344,881 sh (+3.66%)
Ken Fisher 6,015,233 sh (+0.76%)
John Buckingham 84,337 sh (+0.47%)
Pioneer Investments 86,502 sh (unchged)
John Hussman 214,000 sh (unchged)
Murray Stahl 29,425 sh (unchged)
Louis Moore Bacon Sold Out
Dodge & Cox 50,905,449 sh (-0.39%)
Mario Gabelli 10,190 sh (-0.49%)
First Eagle Investment 12,848 sh (-1.62%)
Tweedy Browne 283,983 sh (-1.68%)
PRIMECAP Management 22,239,448 sh (-6.74%)
RS Investment Management 59,008 sh (-23.11%)
Steven Cohen 21,400 sh (-69.21%)
HOTCHKIS & WILEY 9,646 sh (-98.51%)
» More
Q4 2014

NVS Guru Trades in Q4 2014

Jim Simons 860,800 sh (+201.08%)
Lee Ainslie 519,369 sh (+90.55%)
Manning & Napier Advisors, Inc 358,674 sh (+4.00%)
Kahn Brothers 30,968 sh (+1.98%)
Sarah Ketterer 336,278 sh (+0.63%)
HOTCHKIS & WILEY 9,665 sh (+0.20%)
First Eagle Investment 12,848 sh (unchged)
Ruane Cunniff Sold Out
Steven Cohen Sold Out
Ken Fisher 6,007,365 sh (-0.13%)
Murray Stahl 29,367 sh (-0.20%)
PRIMECAP Management 22,168,678 sh (-0.32%)
Dodge & Cox 50,324,645 sh (-1.14%)
Bill Frels 4,280 sh (-1.18%)
John Buckingham 82,902 sh (-1.70%)
Pioneer Investments 82,942 sh (-4.12%)
Mario Gabelli 9,590 sh (-5.89%)
Tweedy Browne 266,037 sh (-6.32%)
John Hussman 164,000 sh (-23.36%)
RS Investment Management 3,000 sh (-94.92%)
» More
Q1 2015

NVS Guru Trades in Q1 2015

Jim Simons 1,227,898 sh (+42.65%)
Mario Gabelli 9,840 sh (+2.61%)
Manning & Napier Advisors, Inc 361,795 sh (+0.87%)
PRIMECAP Management 22,176,613 sh (+0.04%)
Kahn Brothers 30,968 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Pioneer Investments 82,942 sh (unchged)
Lee Ainslie Sold Out
John Buckingham Sold Out
HOTCHKIS & WILEY Sold Out
Ken Fisher 5,990,224 sh (-0.29%)
Dodge & Cox 50,032,795 sh (-0.58%)
Tweedy Browne 260,217 sh (-2.19%)
Bill Frels 4,080 sh (-4.67%)
RS Investment Management 2,825 sh (-5.83%)
Murray Stahl 27,550 sh (-6.19%)
John Hussman 150,000 sh (-8.54%)
Sarah Ketterer 222,652 sh (-33.79%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.15
NVS's P/E(ttm) is ranked higher than
65% of the 469 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.80 vs. NVS: 24.15 )
Ranked among companies with meaningful P/E(ttm) only.
NVS' s 10-Year P/E(ttm) Range
Min: 7.87  Med: 17.47 Max: 26.66
Current: 24.15
7.87
26.66
Forward P/E 18.08
NVS's Forward P/E is ranked higher than
62% of the 244 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. NVS: 18.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.30
NVS's PE(NRI) is ranked higher than
68% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.50 vs. NVS: 22.30 )
Ranked among companies with meaningful PE(NRI) only.
NVS' s 10-Year PE(NRI) Range
Min: 10.63  Med: 17.79 Max: 24.89
Current: 22.3
10.63
24.89
P/B 2.97
NVS's P/B is ranked higher than
57% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. NVS: 2.97 )
Ranked among companies with meaningful P/B only.
NVS' s 10-Year P/B Range
Min: 1.69  Med: 2.51 Max: 4.14
Current: 2.97
1.69
4.14
P/S 4.46
NVS's P/S is ranked lower than
59% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. NVS: 4.46 )
Ranked among companies with meaningful P/S only.
NVS' s 10-Year P/S Range
Min: 1.89  Med: 3.15 Max: 4.92
Current: 4.46
1.89
4.92
PFCF 22.89
NVS's PFCF is ranked higher than
73% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.65 vs. NVS: 22.89 )
Ranked among companies with meaningful PFCF only.
NVS' s 10-Year PFCF Range
Min: 7.03  Med: 17.04 Max: 26.79
Current: 22.89
7.03
26.79
POCF 17.26
NVS's POCF is ranked higher than
70% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.21 vs. NVS: 17.26 )
Ranked among companies with meaningful POCF only.
NVS' s 10-Year POCF Range
Min: 5.75  Med: 13.02 Max: 19.28
Current: 17.26
5.75
19.28
EV-to-EBIT 18.08
NVS's EV-to-EBIT is ranked higher than
62% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.91 vs. NVS: 18.08 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s 10-Year EV-to-EBIT Range
Min: 8.9  Med: 16.20 Max: 23.2
Current: 18.08
8.9
23.2
Shiller P/E 23.55
NVS's Shiller P/E is ranked higher than
70% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.23 vs. NVS: 23.55 )
Ranked among companies with meaningful Shiller P/E only.
NVS' s 10-Year Shiller P/E Range
Min: 9.24  Med: 14.47 Max: 25.93
Current: 23.55
9.24
25.93
Current Ratio 1.39
NVS's Current Ratio is ranked lower than
75% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. NVS: 1.39 )
Ranked among companies with meaningful Current Ratio only.
NVS' s 10-Year Current Ratio Range
Min: 1.04  Med: 1.65 Max: 2.83
Current: 1.39
1.04
2.83
Quick Ratio 1.17
NVS's Quick Ratio is ranked lower than
69% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NVS: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s 10-Year Quick Ratio Range
Min: 0.78  Med: 1.32 Max: 2.48
Current: 1.17
0.78
2.48
Days Inventory 140.32
NVS's Days Inventory is ranked lower than
64% of the 616 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.37 vs. NVS: 140.32 )
Ranked among companies with meaningful Days Inventory only.
NVS' s 10-Year Days Inventory Range
Min: 117.86  Med: 174.34 Max: 297.21
Current: 140.32
117.86
297.21
Days Sales Outstanding 62.95
NVS's Days Sales Outstanding is ranked higher than
58% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.51 vs. NVS: 62.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s 10-Year Days Sales Outstanding Range
Min: 53.85  Med: 64.06 Max: 79.16
Current: 62.95
53.85
79.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.71
NVS's Dividend Yield is ranked higher than
93% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. NVS: 2.71 )
Ranked among companies with meaningful Dividend Yield only.
NVS' s 10-Year Dividend Yield Range
Min: 1.47  Med: 3.11 Max: 5.11
Current: 2.71
1.47
5.11
Dividend Payout 0.63
NVS's Dividend Payout is ranked higher than
79% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. NVS: 0.63 )
Ranked among companies with meaningful Dividend Payout only.
NVS' s 10-Year Dividend Payout Range
Min: 0.22  Med: 0.43 Max: 0.67
Current: 0.63
0.22
0.67
Dividend growth (3y) 6.80
NVS's Dividend growth (3y) is ranked lower than
51% of the 246 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. NVS: 6.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
NVS' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 7.45 Max: 18.5
Current: 6.8
0
18.5
Yield on cost (5-Year) 3.96
NVS's Yield on cost (5-Year) is ranked higher than
93% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. NVS: 3.96 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVS' s 10-Year Yield on cost (5-Year) Range
Min: 2.14  Med: 4.53 Max: 7.44
Current: 3.96
2.14
7.44
Share Buyback Rate -0.20
NVS's Share Buyback Rate is ranked higher than
70% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.40 vs. NVS: -0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
NVS' s 10-Year Share Buyback Rate Range
Min: 41.9  Med: 0.90 Max: -2.5
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 26.63
NVS's Price/Tangible Book is ranked lower than
95% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. NVS: 26.63 )
Ranked among companies with meaningful Price/Tangible Book only.
NVS' s 10-Year Price/Tangible Book Range
Min: 0.16  Med: 4.28 Max: 35.33
Current: 26.63
0.16
35.33
Price/Projected FCF 1.49
NVS's Price/Projected FCF is ranked higher than
77% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. NVS: 1.49 )
Ranked among companies with meaningful Price/Projected FCF only.
NVS' s 10-Year Price/Projected FCF Range
Min: 0.76  Med: 0.97 Max: 1.53
Current: 1.49
0.76
1.53
Price/Median PS Value 1.37
NVS's Price/Median PS Value is ranked lower than
55% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. NVS: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
NVS' s 10-Year Price/Median PS Value Range
Min: 0.75  Med: 1.15 Max: 1.69
Current: 1.37
0.75
1.69
Price/Graham Number 3.62
NVS's Price/Graham Number is ranked lower than
60% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.75 vs. NVS: 3.62 )
Ranked among companies with meaningful Price/Graham Number only.
NVS' s 10-Year Price/Graham Number Range
Min: 0.07  Med: 1.99 Max: 4.84
Current: 3.62
0.07
4.84
Earnings Yield (Greenblatt) (%) 5.57
NVS's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. NVS: 5.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4.3  Med: 6.20 Max: 11.3
Current: 5.57
4.3
11.3
Forward Rate of Return (Yacktman) (%) 1.73
NVS's Forward Rate of Return (Yacktman) (%) is ranked lower than
60% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. NVS: 1.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVS' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.3  Med: 14.40 Max: 81.5
Current: 1.73
1.3
81.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, ABT » details
Traded in other countries:0HKE.UK, NOVN.Switzerland, NOT.Germany, NOTA.Germany, NVS.Argentina, NVS N.Mexico, NOVNEE.Switzerland, NVSEF.USA,
Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includes innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and they report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVS

Headlines

Articles On GuruFocus.com
Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
Bill Frels' Stocks With Growing Yields Jun 27 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
Billionaire George Soros Ups Two Stakes in First Quarter Jun 16 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 

More From Other Websites
Biogen: Where Did That Come From? Jul 02 2015
US seeks $3.3 bn corruption fine from Novartis Jul 01 2015
U.S. Seeks $3.3 Billion From Novartis in Drug Kickback Suit Jul 01 2015
2:17 am Novartis' Alcon receives EU approval for its AcrySof IQ Aspheric IOL with the UltraSert... Jul 01 2015
US seeks $3.3 bn corruption fine from Novartis Jun 30 2015
Novartis (NVS) Stock Declines as U.S. Seeks $3.35 Billion Fine Jun 30 2015
How Much?! Feds Wants Novartis to pay $3.35B For Kickback Schemes Jun 30 2015
U.S. seeks up to $3.35 billion in Novartis kickback lawsuit Jun 30 2015
Roche 'High Efficacy' MS Drug Succeeds In Trials Jun 30 2015
Novartis' Cosentyx Positive in Psoriatic Arthritis Study - Analyst Blog Jun 29 2015
Early movers: NBG, JPM, M, GCI, TWTR & more Jun 29 2015
Novartis to Pay at Least $200 Million for Chronic Pain Medicine Jun 29 2015
Switzerland's Novartis buys US biotech firm Spinifex Jun 29 2015
Novartis buys Spinifex for $US200m plus Jun 29 2015
Novartis buys pain drug firm Spinifex for $200 mln upfront Jun 29 2015
Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc. Jun 29 2015
New data fuel hopes for broad use of Novartis psoriasis drug Jun 28 2015
External Innovation: Force Multiplier For R&D Jun 26 2015
Europe gives green light to new Novartis, Alexion drugs Jun 26 2015
Hagens Berman: Class Action Alleges Novartis Gleevec Patent Infringement Suit a Sham Jun 24 2015
Cancer Therapy Boosts Appeal of Juno, Kite as Targets: Real M&A Jun 23 2015
GSK Vaccinates Pfizer to Gain Novartis - Video Blog Jun 23 2015
Pfizer to buy two vaccines from Glaxo Jun 22 2015
GSK sells two meningitis drugs to Pfizer for £82m Jun 22 2015
Novartis AG upgraded by Bryan Garnier Jun 22 2015
Novartis AG (NVS) Stock Rises on Plan to Increase Profit Margin Jun 18 2015
Novartis flags margin increase, higher dividends, bolt-on deals Jun 18 2015
Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for... Jun 16 2015
Novartis Presents Data on Leukemia, Dermatology Drugs - Analyst Blog Jun 15 2015
Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna®... Jun 13 2015
Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with... Jun 12 2015
Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic... Jun 12 2015
Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed... Jun 12 2015
Novartis India arm says unaware of any delisting plan Jun 11 2015
Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing... Jun 10 2015
Novartis places big, broad bet on cancer immunotherapy Jun 08 2015
Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 Jun 04 2015
Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients... Jun 04 2015
Novartis highlights CTL019 data showing its potential in the treatment of specific types of... Jun 04 2015
Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in... Jun 04 2015
Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced... Jun 04 2015
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in... Jun 04 2015
Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA Jun 04 2015
Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term... Jun 02 2015
Novartis highlights CTL019 data showing its potential in the treatment of specific types of... Jun 01 2015
Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in... Jun 01 2015
Novartis digs into health tech with bet on "robotic pill" May 27 2015
Novartis digs into health tech with bet on 'robotic pill' May 27 2015
GlaxoSmithKline opts to hold on to HIV business May 06 2015
GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
GSK cuts Novartis payout as first-quarter revenues rise but earnings ease May 06 2015
GlaxoSmithKline plc Pleases The Market With New Strategic 5-Year Plan May 06 2015
Drugs giant GSK says net profits soar May 06 2015
New-look GSK bets on consumer health spending May 06 2015
Interview - New-look GSK bets on consumer health spending May 06 2015
Interview - New-look GSK bets on consumer health spending May 06 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
Doubts grow over GlaxoSmithKline's 4 billion pound capital return plan May 01 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
ImmunoGen skids after disclosing drug development setbacks Apr 27 2015
Novartis keeps full-year target as Q1 earnings fall Apr 23 2015
Novartis posts Q1 profit beat despite dollar drag Apr 23 2015
Novartis posts Q1 profit beat despite dollar drag Apr 23 2015
Divestment gains boost net earnings at drug company Novartis Apr 23 2015
Novartis warns of currency drag on 2015 earnings Apr 23 2015
Novartis confirms 2015 guidance after first-quarter profit beat Apr 23 2015
Novartis confirms 2015 guidance after Q1 profit beat Apr 23 2015
FDA approves generic version of top-selling MS drug Copaxone Apr 17 2015
FDA approves new type of heart failure drug from Amgen Apr 15 2015
Global generic drugs market sees FDA approve new type of generic drugs made from living cells Mar 30 2015
Novartis digs deeper into cancer with up to $750 million Aduro deal Mar 30 2015
GSK agrees UK deal for meningitis shot after Novartis stand-off Mar 29 2015
Novartis unit hit with $110 million gender discrimination suit Mar 17 2015
GSK and Novartis complete deals to reshape both drugmakers Mar 02 2015
GSK and Novartis complete deals to reshape both drugmakers Mar 02 2015
GSK and Novartis complete deals to reshape both drugmakers Mar 02 2015
GSK set to complete 13 billion pounds Novartis asset swap next week Feb 25 2015
GSK set to complete $20 bln Novartis asset swap next week Feb 25 2015
FDA approves Novartis drug for bone marrow cancer Feb 23 2015
Novartis AG wins approval to buy GSK cancer drugs, with conditions Feb 23 2015
Australian regulator says will not oppose GSK, Novartis deals Feb 19 2015
EU puts conditions on deals involving Novartis, GSK Jan 28 2015
EU clears plans by drugmakers GSK and Novartis to trade assets Jan 28 2015
Novartis sues Cipla over respiratory drug Onbrez Dec 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK